Reata Pharmaceuticals, Inc. - (RETA) Social Stream
REATA PHARMACEUTICALS INC (RETA) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering REATA PHARMACEUTICALS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 8 | $282 | $155 | $220.25 | $172.36 | 27.78% |
| 2021-12-07 | 7 | $282 | $112 | $205.875 | $172.36 | 19.44% |
| 2021-12-09 | 8 | $244 | $35 | $94.625 | $172.36 | -45.1% |
| 2022-03-01 | 8 | $244 | $35 | $80.625 | $172.36 | -53.22% |
| 2022-03-02 | 8 | $244 | $35 | $80.875 | $172.36 | -53.08% |
| 2022-05-04 | 6 | $244 | $35 | $80.875 | $172.36 | -53.08% |
| 2022-05-11 | 8 | $244 | $35 | $81.111 | $172.36 | -52.94% |
| 2022-05-24 | 7 | $75 | $35 | $58.5 | $172.36 | -66.06% |
| 2022-08-09 | 8 | $75 | $35 | $57.111 | $172.36 | -66.87% |
| 2022-08-11 | 8 | $75 | $27 | $51 | $172.36 | -70.41% |
| 2022-10-11 | 8 | $75 | $27 | $51.222 | $172.36 | -70.28% |
| 2022-10-19 | 9 | $75 | $27 | $53.6 | $172.36 | -68.9% |
| 2022-11-08 | 10 | $75 | $27 | $53.6 | $172.36 | -68.9% |
| 2022-11-09 | 10 | $86 | $27 | $58.2 | $172.36 | -66.23% |
| 2023-02-12 | 10 | $115 | $27 | $61.1 | $172.36 | -64.55% |
| 2023-02-24 | 10 | $117 | $27 | $61.3 | $172.36 | -64.43% |
| 2023-03-02 | 10 | $185 | $49 | $101 | $172.36 | -41.4% |
| 2023-04-11 | 10 | $185 | $75 | $106.9 | $172.36 | -37.98% |
| 2023-04-13 | 10 | $185 | $75 | $107.9 | $172.36 | -37.4% |
| 2023-05-11 | 10 | $185 | $75 | $107.8 | $172.36 | -37.46% |
| 2023-06-15 | 10 | $185 | $75 | $110.6 | $172.36 | -35.83% |
| 2023-06-28 | 10 | $185 | $75 | $111.8 | $172.36 | -35.14% |
| 2023-06-29 | 10 | $185 | $75 | $113.6 | $172.36 | -34.09% |
| 2023-07-23 | 11 | $185 | $75 | $116 | $172.36 | -32.7% |
| 2023-07-24 | 11 | $185 | $75 | $119.181 | $172.36 | -30.85% |
| 2023-07-31 | 11 | $185 | $75 | $136.318 | $172.36 | -20.91% |
| 2023-08-02 | 11 | $185 | $75 | $154.318 | $172.36 | -10.47% |
| 2023-08-15 | 10 | $173 | $75 | $162.7 | $172.36 | -5.6% |
The Trend in the Analyst Price Target
Over the past 21 months, RETA's average price target has gone down $55.52.
RETA reports an average of 19.99% for its upside potential over the past 44 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-11-09 | 10 | 86 | 27 | 56.200 | 38.27 | 46.85% |
| 2023-05-11 | 10 | 185 | 75 | 107.100 | 88.01 | 21.69% |
| 2023-06-12 | 10 | 185 | 75 | 110.600 | 99.12 | 11.58% |
| 2023-06-29 | 10 | 185 | 75 | 113.600 | 100.90 | 12.59% |
| 2023-08-02 | 11 | 185 | 75 | 154.318 | 166.51 | -7.32% |
RETA Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.8 | 1 | 0 | 9 | 0 | 0 | 10 |
The Trend in the Broker Recommendations
RETA's average broker recommendation rating worsened by 1.14 over the prior 19 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for RETA as an investment opportunity.
- REATA PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is higher than 183.09% of all US stocks.
- In terms of how REATA PHARMACEUTICALS INC fares relative to stocks in the mid market cap category, note that its variance in analysts' estimates is lower than -3358.75% of that group.
- RETA has a higher average analyst price target than 3273.36% of Pharmaceutical Products stocks.
- In terms of how REATA PHARMACEUTICALS INC fares relative to stocks in the mid market cap category, note that its number of analysts covering the stock is greater than 2578.8% of that group.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to REATA PHARMACEUTICALS INC are AXSM, MCRB, and ASND.
View All Top Stocks by Price Target
Is RETA a Buy, Hold or Sell? See the POWR Ratings now!